The pharmaceutical community is excited by retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant results in early studies . This medication works by imitating natural hormones to regulate appetite and promote feelings of satisfaction , ultimately leading considerable body reduction . While still under review and not read